CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.

Autor:	Muccini C; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute., Gianotti N; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute., Lolatto R; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute., Nozza S; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute.; Vita-Salute San Raffaele University, Milan, Italy., Diotallevi S; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute., Castagna A; Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute.; Vita-Salute San Raffaele University, Milan, Italy.
Jazyk:	angličtina
Zdroj:	AIDS (London, England) [AIDS] 2024 Nov 01; Vol. 38 (13), pp. 1890-1892. Date of Electronic Publication: 2024 Sep 26.
DOI:	10.1097/QAD.0000000000003984
Abstrakt:	Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu